Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …

Epstein Barr virus (EBV) is a cosmopolitan oncogenic virus, infecting about 90% of the
world's population and it is associated to tumors originating from both epithelia and …

Human B cells are the primary targets of Epstein–Barr virus (EBV) infection. In most cases,
EBV infection is asymptomatic because of a highly effective host immune response, but …

Adoptive immunotherapy with transplant donor-derived virus-specific T cells has emerged
as a potentially curative approach for the treatment of drug-refractory EBV+ lymphomas as …

Post-transplant lymphoproliferative disorders (PTLDs) are a group of conditions that involve
uncontrolled proliferation of lymphoid cells as a consequence of extrinsic …

SUMMARY Epstein-Barr virus (EBV) DNA measurement is being incorporated into routine
medical practice to help diagnose, monitor, and predict posttransplant lymphoproliferative …

Posttransplant lymphoproliferative disorder (PTLD) is recognized as potentially one of the
most devastating complications of organ transplantation. The Epstein–Barr virus (EBV) …

Posttransplant lymphoproliferative disease (PTLD) is a potentially fatal complication after
(solid organ) transplantation, which is highly associated with Epstein-Barr virus (EBV). The …

A higher risk for a variety of cancers is among the major complications of posttransplantation
immunosuppression. In this part of a continuing series on cancers posttransplantation, this …

Infectious complications remain a leading cause of morbidity and mortality after solid organ
transplantation (SOT), and largely depend on the net state of immunosuppression achieved …